Phase 2 N=34 Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Schizophrenia
Primary: Adverse Events — 10; 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=264 Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Neoplasms
Primary: Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) — 1; 1; 2; 7 Participants
N/A N=40 A Study to Asses Wellness Using a Brain Sensing Device on Physicians
Stress, Emotional · Sleep · Quality of Life
Primary: Frequency Adherence to Intervention — 57.8 times used
N/A N=100 Study of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device
Left Atrial Appendage Occlusion
Primary: Successful Implantation of WATCHMAN FLX Device — 96 Participants
N/A N=805 Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma
Non-squamous, Non-Small Cell Lung Cancer
Primary: Time on Treatment (TOT) With Afatinib in First-line TOT (TOT1) — 0.39; 0.15 Proportion of participants
N/A N=187 Clinical Evaluation of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Determination of Presence or Absence of Significant PAD With BVE and Arterial Duplex — 62; 14; 212; 43 Limbs
Phase 1 N=36 Study of DCR-AUD in Healthy Volunteers
Alcohol Use Disorder (AUD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 5; 4; 2 Participants
Phase 3 N=166 A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 162; 44 Participants
Phase 2 N=35 A Study of Nivolumab in Selected Uterine Cancer Patients
Uterine Cancer · Endometrial Carcinoma · Carcinosarcoma
Primary: Progression-Free Survival — 64.7 percentage of patients
Phase 2 N=18 Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma · Fumarate Hydratase Deficient Renal Cell Carcinoma · Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Primary: the Objective Response Rate (ORR) — 0; 0; 10; 8 Participants
N/A N=45 An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8
Primary: Percentage of Participants Accrued to the Study (Feasibility) — 45 Participants
Phase 4 N=444 Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Admission Rate — 98; 188 Participants
Phase 2 N=8 Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Multiple Sclerosis
Primary: Modulation of One or All Paramagnetic Rim Lesions — .04 proportion of rim lesions modulated
Phase 2 N=60 Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Isolated Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Achieved Platelet Counts of ≥ 100,000/mcL — 93 percentage of participants
N/A N=60 A Mobile Health Intervention to Reduce Diabetes Disparities in Chinese Americans
Type2 Diabetes
Primary: Change in Average Plasma Glucose Concentration Measured by Hemoglobin A1c (HbA1c) Levels — -0.68; -0.95 Percentage